Australia - English - Department of Health (Therapeutic Goods Administration)

celgene pty ltd - thalidomide, quantity: 100 mg - capsule, hard - excipient ingredients: magnesium stearate; pregelatinised maize starch; propylene glycol; ethanol; butan-1-ol; purified water; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide; gelatin; sodium lauryl sulfate - multiple myeloma - thalomid in combination with melphalan and prednisone is indicated for the treatment of patients with untreated multiple myeloma aged 65 years and over or ineligible for high dose chemotherapy. thalomid in combination with dexamethasone is indicated for induction therapy prior to high dose chemotherapy with autologous stem cell rescue, for the treatment of patients with untreated multiple myeloma. thalomid, as monotherapy, is indicated for the treatment of multiple myeloma after failure of standard therapies. erythema nodosum leprosum (enl). thalomid is indicated for the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (enl). thalomid is not indicated as monotherapy for such enl treatment in the presence of moderate to severe neuritis. thalomid is also indicated as maintenance therapy for prevention and suppression of the cutaneous manifestations of enl recurrence. thalomid is prescribed and dispensed through the thalidomide risk management programme. multiple myeloma - thalomid in combination with melphalan and prednisone is indicated for the treatment of patients with untreated multiple myeloma aged 65 years and over or ineligible for high dose chemotherapy. thalomid in combination with dexamethasone is indicated for induction therapy prior to high dose chemotherapy with autologous stem cell rescue, for the treatment of patients with untreated multiple myeloma. thalomid, as monotherapy, is indicated for the treatment of multiple myeloma after failure of standard therapies. erythema nodosum leprosum (enl). thalomid is indicated for the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (enl). thalomid is not indicated as monotherapy for such enl treatment in the presence of moderate to severe neuritis. thalomid is also indicated as maintenance therapy for prevention and suppression of the cutaneous manifestations of enl recurrence.

Australia - English - Department of Health (Therapeutic Goods Administration)

celgene pty ltd - thalidomide, quantity: 50 mg - capsule, hard - excipient ingredients: magnesium stearate; pregelatinised maize starch; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide; titanium dioxide; gelatin - multiple myeloma - thalomid in combination with melphalan and prednisone is indicated for the treatment of patients with untreated multiple myeloma aged 65 years and over or ineligible for high dose chemotherapy. thalomid in combination with dexamethasone is indicated for induction therapy prior to high dose chemotherapy with autologous stem cell rescue, for the treatment of patients with untreated multiple myeloma. thalomid, as monotherapy, is indicated for the treatment of multiple myeloma after failure of standard therapies. erythema nodosum leprosum (enl). thalomid is indicated for the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (enl). thalomid is not indicated as monotherapy for such enl treatment in the presence of moderate to severe neuritis. thalomid is also indicated as maintenance therapy for prevention and suppression of the cutaneous manifestations of enl recurrence. multiple myeloma - thalomid in combination with melphalan and prednisone is indicated for the treatment of patients with untreated multiple myeloma aged 65 years and over or ineligible for high dose chemotherapy. thalomid in combination with dexamethasone is indicated for induction therapy prior to high dose chemotherapy with autologous stem cell rescue, for the treatment of patients with untreated multiple myeloma. thalomid, as monotherapy, is indicated for the treatment of multiple myeloma after failure of standard therapies. erythema nodosum leprosum (enl). thalomid is indicated for the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (enl). thalomid is not indicated as monotherapy for such enl treatment in the presence of moderate to severe neuritis. thalomid is also indicated as maintenance therapy for prevention and suppression of the cutaneous manifestations of enl recurrence. thalomid is prescribed and dispensed through the thalidomide risk management programme.

Israel - English - Ministry of Health

neopharm ltd - thalidomide - hard capsule - thalidomide 50 mg - thalidomide - multiple myeloma : * for the treatment of multiple myeloma after failure of standard therapies. * thalidomide bms 50 mg hard capsules in combination with dexamethasone is indicated for the treatment of patients with newly diagnosed multiple myeloma. * thalidomide bms in combination with melphalan and prednisone is indicated for the treatment of patients with untreated multiple myeloma > or = 65 years or ineligible for high dose chemotherapy. erythema nodosum leprosum: for the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (enl). thalidomide is not indicated as monotherapy for such enl treatment in the presence of moderate to severe neuritis. it is also indicated as maintenance therapy for prevention and suppression of the cutaneous manifestations of enl recurrence.

Israel - English - Ministry of Health

neopharm ltd - thalidomide - hard capsule - thalidomide 50 mg - thalidomide - multiple myeloma : 1. for the treatment of multiple myeloma after failure of standars therapies. 2. thalidomide celgene 50 mg hard capsules in combination with dexamethasone is indicated for the treatment of patients with newly diagnosed multiple myeloma. 3. thalidomide celgene in combination with melphalan and prednisone is indicated for the treatment of patients with untreated multiple myeloma > or = 65 years or ineligible for high dose chemotherapy. erythema nodosum leprosum: 4. for the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (enl). thalidomide is not indicated as monotherapy for such enl treatment in the presence of moderate to severe neuritis. it is also indicated as maintenance therapy for prevention and suppression of the cutaneous manifestations of enl recurrence.בקשה לעדכון משטר מינון 4/2/2020

Australia - English - Department of Health (Therapeutic Goods Administration)

celgene pty ltd - thalidomide, quantity: 200 mg - capsule, hard - excipient ingredients: magnesium stearate; pregelatinised maize starch; titanium dioxide; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; pharmaceutical glaze; dimeticone; purified water; gelatin; sodium lauryl sulfate - multiple myeloma - thalomid in combination with melphalan and prednisone is indicated for the treatment of patients with untreated multiple myeloma aged 65 years and over or ineligible for high dose chemotherapy. thalomid in combination with dexamethasone is indicated for induction therapy prior to high dose chemotherapy with autologous stem cell rescue, for the treatment of patients with untreated multiple myeloma. thalomid, as monotherapy, is indicated for the treatment of multiple myeloma after failure of standard therapies. erythema nodosum leprosum (enl). thalomid is indicated for the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (enl). thalomid is not indicated as monotherapy for such enl treatment in the presence of moderate to severe neuritis. thalomid is also indicated as maintenance therapy for prevention and suppression of the cutaneous manifestations of enl recurrence. thalomid is prescribed and dispensed through the thalidomide risk management pro

Australia - English - Department of Health (Therapeutic Goods Administration)

celgene pty ltd - thalidomide, quantity: 150 mg - capsule, hard - excipient ingredients: magnesium stearate; pregelatinised maize starch; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; ethanol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide; titanium dioxide; sorbitan monolaurate; caramel; potable water; gelatin; sodium lauryl sulfate; pharmaceutical glaze; dimeticone - multiple myeloma - thalomid in combination with melphalan and prednisone is indicated for the treatment of patients with untreated multiple myeloma aged 65 years and over or ineligible for high dose chemotherapy. thalomid in combination with dexamethasone is indicated for induction therapy prior to high dose chemotherapy with autologous stem cell rescue, for the treatment of patients with untreated multiple myeloma. thalomid, as monotherapy, is indicated for the treatment of multiple myeloma after failure of standard therapies. erythema nodosum leprosum (enl). thalomid is indicated for the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (enl). thalomid is not indicated as monotherapy for such enl treatment in the presence of moderate to severe neuritis. thalomid is also indicated as maintenance therapy for prevention and suppression of the cutaneous manifestations of enl recurrence. multiple myeloma - thalomid in combination with melphalan and prednisone is indi

Australia - English - Department of Health (Therapeutic Goods Administration)

link medical products pty ltd t/a link pharmaceuticals - dapsone, quantity: 100 mg - tablet, uncoated - excipient ingredients: maize starch; magnesium stearate; silicon dioxide; microcrystalline cellulose - dermatitis herpetiformis. leprosy. actinomycotic mycetoma.

Australia - English - Department of Health (Therapeutic Goods Administration)

link medical products pty ltd t/a link pharmaceuticals - dapsone, quantity: 25 mg - tablet, uncoated - excipient ingredients: silicon dioxide; magnesium stearate; microcrystalline cellulose; maize starch - dermatitis herpetiformis. leprosy. actinomycotic mycetoma.

Philippines - English - FDA (Food And Drug Administration)

jw healthcare philippines corporation; distributor: jw healthcare philippines corporation - amino acids - solution for iv infusion - 0.085

Philippines - English - FDA (Food And Drug Administration)

jw healthcare philippines corporation; distributor: jw healthcare philippines corporation - amino acids - solution for i.v infusion - 0.054